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Introduction
It has been estimated that approximately 5% of all
postmenopausal women develop hypothyroidism,
mainly due to autoimmune thyroiditis [1]. Progressive
estrogens deficit leads to bone mass loss, reduced
skeletal strength and increased susceptibility to frac-
tures. Estrogen depletion after menopause is accompa-
nied by an increase in the production of several
osteotropic cytokines, such as IL-6, IL-10 and Tumor
Necrosis Factor (TNF) [2,3]. IL-6 is a pleiotropic
cytokine secreted by osteoblasts, osteoclasts and stro-
mal cells that regulates bone remodeling by promoting
differentiation of osteoclasts- cells responsible for
bone resorption [4]. However in conditions of active
bone metabolism IL-6 may also stimulate osteoblast
generation [5]. In ovariectomized mice IL-6 was
shown to play a key role in bone turnover acceleration
and selective inhibitor of IL-6 was documented to
effectively suppress bone mass reduction [6,7]. The
influence of hypothyroidism on bone metabolism in
women in postmenopausal age is poorly understood.
IL-6 may exert its inhibitory effect on bone forma-
tion directly through gp130-STAT 1/3 signaling or
indirectly by influencing balance between osteoprote-
gerin (OPG) and receptor activator of nuclear factor
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κB (RANK) and its ligand (RANKL) [5,8]. The influ-
ence of IL-6 on RANK-RANKL/OPG system was
suggested to be powerful mechanism leading to
increased bone mass loss [9]. Our experimental data
suggest important influence of IL-6 on bone turnover
in thyrotoxicosis and minor role of this cytokine in
bone metabolism in hypothyroid state [10,11]. Data on
IL-6 involvement in RANK-RANKL/OPG balance in
conditions coexisting with estrogen deficit (connected
with accelerated bone turnover) and hypothyroidism
(causing a slowdown of bone metabolism) are lacking.
The aim of the present study was an attempt to clar-
ify the role of interleukin-6 on RANKL-RANK/osteo-
protegerin system in hypothyroid ovariectomized mice.
Material and methods
Experimental animals. The study was performed on 56, 12-13
weeks old, female mice: C57BL/6J (wild-type; WT) and
C57BL/6JIL6-/-Kopf (IL-6 knock-out; IL6KO). All animals had free
access to standard granulated diet and drinking water. The animals
were housed in plastic cages at 22±1°C and constant humidity,
with a 12/12 light/dark cycle, beginning at 7 am. The mice were
randomly divided into 8 groups with 7 mice in each one: 1/ WT
controls (WT), 2/ IL6KO controls (IL6KO), 3/ WT mice hypothy-
roid (WT-PTU), 4/ IL6KO hypothyroid (IL6KO-PTU), 5/ WT
ovariectomized (WT-Ox), 6/ IL6KO ovariectomized (IL6KO-Ox),
7/ WT hypothyroid ovariectomized (WT-PTU-Ox) and 8/ IL6KO
hypothyroid ovariectomized mice (IL6KO-PTU-Ox). 
Experimental model of menopause was produced by bilateral
ovariectomy carried out in 8 – 9 weeks old mice under ketamine
(100 mg/kg) and xylazine-HCL (10 mg/kg) anesthesia. After their
abdomen was opened by midline incision both ovaries were resect-
ed. After surgery mice were kept for 24 hours in cages heated up to
27°C for recovery, with water and chow available ad libitum. Con-
trol mice were sham-operated under similar conditions.
Experimental model of hypothyroidism was induced by admin-
istration of 0.1% solution of propylthiouracyl (PTU) in drinking
water at the dose of 60 μg/kg daily over 21 days. Control mice were
injected vehicle under the same experimental conditions.
Genotyping. Genomic DNA for IL-6 genotyping was isolated
from mouse tails using "Genomic mini" kit (A&A Biotechnology,
Gdansk, Poland) according to the enclosed protocol. PCR was per-
formed using Master Mix (2×) (Fermentas) and custom made
primers (F 5'-CCATCCAGTTGCCTTCTTG-3', R 5'-AAGTGCAT
CATCGTTGTTCATAC-3'). 
After initial denaturation in 94°C over 5 minutes, amplification
was performed in thirty PCR cycles under following conditions:
94°C 20 seconds, 52°C 30 seconds, 72°C 
3 minutes, with final extension in 72°C 10 minutes, and in 4°C
at the end of the procedure. Then DNA was separated by elec-
trophoresis on 1% agarose gel with ethidium bromide.
Blood specimens. At the end of the experiment, the animals were
anesthetized with ketamine (100 mg/kg) and xylazine-HCL (10
mg/kg), their abdomen was opened by midline incision and the
blood was taken from the abdominal aorta of each mouse for meas-
urement of serum concentrations of osteoclast-derived tartrate-
resistant acid phosphatase form 5a (TRACP5b), osteocalcin, OPG,
RANKL and creatinine. The blood was collected to polypropylene
tubes without anticoagulant and was incubated in room tempera-
ture until the clot was formed and then centrifuged (2500 × g, 15
minutes). The supernatant (serum) was removed and stored at -
70°C until a consecutive analysis. The serum levels of TRACP5b
and osteocalcin were determined by enzyme-linked immunosor-
bent assay commercial kits: TRACP5b (MouseTRAP Assay, SBA
Sciences, Turku, Finland; sensitivity 0.1 U/l; intra-assay precision
6.5%; inter-assay variation 8%) and osteocalcin (Mouse Osteocal-
cin EIA kit, Biomedical Technologies Inc., Stoughton, USA; sen-
sitivity 1 ng/ml; intra-assay precision 6%; inter-assay variation
8%). The serum concentrations of RANKL (sRANKL) and OPG
were estimated by enzyme immunoassay commercial kits:
RANKL (Quantikine, R&D Systems, Abingdon, UK; sensitivity 5
pg/ml; intra-assay precision 2.2%; inter-assay variation 6.5%) and
OPG (Quantikine, R&D Systems, Abingdon, UK; sensitivity 4.5
pg/ml; intra-assay precision 5.5%; inter-assay variation 7.3%).
Serum creatinine concentration was measured by autoanalyzer
using standard laboratory methods. 
Thyroid tissues. To verify an animal model of hypothyroidism
(immediately after taking a blood) mice were thyreoidectomized.
Both thyroid lobes were fixed in Bouin's fluid for 24 hours in tem-
perature of +4°C and embedded in paraffin in a routine procedure.
The specimens were cut into 5 μm slices and stained by haema-
toxylin-eosin. The histological preparations were subjected to
analysis, using Olympus Bx50 microscope.
Osteodensitometry. Bone mineral density (BMD) was examined
in a-p position by the dual X-ray absorptiometry using Lunar DPX
densitometer (Lunar Corporation, Madison, WI) with small animal
software. BMD measurements were performed by the same expe-
rienced operator. The densitometer was calibrated everyday with a
standard phantom specimen. The following sites were examined:
the total body, tibia, trochanter and vertebrae L2-L4. BMD values
were estimated in mg/cm2. 
Ethical issues. All procedures were performed in compliance with
the European Communities Council Directive of 24 November
1986 (86/609/EEC) and were approved by the Local Ethics Com-
mittee in Bialystok.
Statistical analysis. The statistical significance was estimated by
Mann-Whitney U-test. To evaluate relationships between variables
Spearman's test was performed using Statistica 9.0 for Windows
XP (StatSoft, Tulsa, USA).
Results
IL-6 genotyping
Material from wild-type animals yielded DNA frag-
ments with size ca. 1476 bp, whereas DNA frag-
ments from IL6KO animals contained also a frag-
ment of neomycin cassette and were size about 2400
bp (Fig. 1).
Bone turnover serum markers
As it is shown in Fig. 2 and 3, serum concentrations of
TRACP 5b and osteocalcin were significantly
decreased in propylthiouracyl injected sham-operated
IL6-deficient mice. Moreover TRACP 5b values were
significantly decreased in both wild-type and IL6KO
ovariectomized hypothyroid mice as compared to
euthyroid groups of ovariectomized animals. Osteocal-
cin serum concentrations were increased in all groups
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of ovariectomized mice. Serum concentrations of
TRACP 5b (median and interquartile ranges) were
respectively: WT (16.4 (13.1-22.0) U/l), IL6KO (12.2
(10.2-15.5) U/l), WT-PTU (9.9 (7.6-13.2) U/l),
IL6KO-PTU (8.0 (6.5-10.8) U/l), WT-Ox (17.2 (15.1-
19.6) U/l), IL6KO-Ox (15.5 (12.0-19.3) U/l), WT-
PTU-Ox (10.0 (9.1-11.1) U/l) and IL6KO-PTU-Ox
(9.2 (7.7-11.6) U/l). Serum levels of osteocalcin
(median and interquartile ranges) were respectively:
WT (35.8 (31.3-42.5) ng/ml), IL6KO (24.8 (24.8-35.7)
ng/ml), WT-PTU (34.2 (25.7-41.3) ng/ml), IL6KO-
PTU (15.2 (10.2-19.6) ng/ml), WT-Ox (50.9 (44.6-
58.2) ng/ml), IL6KO-Ox (44.5 (38.7-55.3) ng/ml),
WT-PTU-Ox (47.1 (38.7-55.3) ng/ml) and IL6KO-
PTU-Ox (41.4 (32.1-47.3) ng/ml). In all studied mice
TRACP5b and osteocalcin were positively correlated
(R=0.40; p<0.01).
As shown in Fig.4 serum RANKL concentrations
were elevated significantly in wild-type ovariec-
tomized mice as compared to controls. Serum RANKL
value was significantly lower in IL6KO ovariec-
tomised hypothyroid mice as compared to wild-type
animals. Moreover sRANKL values were significantly
lower in IL6KO as compared to WT controls and
IL6KO PTU injected mice. All sRANKL concentra-
tions (median and interquartile ranges) were respec-
tively: WT (97.9 (79.6-123.8) pg/ml), IL6KO (67.9
(61.4-82.9) pg/ml), WT-PTU (95.5 (88.0-117.4)
pg/ml), IL6KO-PTU (96.3 (86.3-109.75) pg/ml), WT-
Ox (137.8 (123.8-154.7) pg/ml), ), IL6KO-Ox (122.6
(107.6-146.0) pg/ml), WT-PTU-Ox (140.6 (122.6-
152.2) pg/ml) and IL6KO-PTU-Ox (117.4 (109.1-
125.4) pg/ml). As shown in Fig. 6 sRANKL values
were positively correlated with osteocalcin concentra-
tions in all studied animals (R=0.45; p<0.001). As
illustrated in Fig. 5 osteoprotegerin serum levels were
decreased in all IL-6 deficient mice and in a highest
degree in sham-operated hypothyroid mice. Serum
concentrations of osteoprotegerin (median and
interquartile ranges) were respectively: WT (2253
(2002-2414) pg/ml), IL6KO (1716 (1601-1892)
pg/ml), WT-PTU (1995 (1857-2072) pg/ml), IL6KO-
PTU (977 (834-1195) pg/ml), WT-Ox (2028 (1703-
2367) pg/ml), IL6KO-Ox (1695 (1439-1843) pg/ml),
WT-PTU-Ox (2118 (1885-2387) pg/ml) and IL6KO-
PTU-Ox (1869 (1671-2065) pg/ml). We have found
positive correlation between osteoprotegerin serum
concentrations and osteocalcin values (R=0.40;
p<0.01). 
There were no significant differences in creatinine
serum concentration in studied groups of mice (data
not shown).
Thyroid specimens
The efficacy of the animal model of hypothyroidism
has been confirmed by the histological picture of thy-
roid glands. The thyroids had a follicular, encapsulat-
ed structure in the control and experimental mice. The
differences between the central and peripheral follicles
in thyroids obtained from both IL6KO and WT control
mice were observed. The central follicles had a small-
er diameter, the colloid was less dense, and the follic-
ular epithelium was higher, whereas the peripheral fol-
licles were larger filled with intensely stained homog-
enous colloid, delimited by flat cuboid epithelium.
Examination of thyroid sections of IL6KO and WT
animals treated with propylthiouracyl pointed to thy-
roid function blockade with predominance of micro-
follicular hyperplasia with poor in colloid hyperplastic
follicles of irregular shape.
Osteodensitometry
No significant differences in BMD between groups
were found (data not shown).
Discussion
In the present study serum TRACP5b concentration, as
a marker of bone resorption, was found to be
decreased in all groups of hypothyroid mice but osteo-
protegerin serum level, as a marker of bone formation,
was diminished only in sham-operated PTU injected
animals. These data are similar to results of our previ-
ous study [11]. Furthermore, in the present study
TRACP5b and osteocalcin measurements have shown
that ovariectomy did not influenced significantly bone
resorption marker but efficiently stimulated bone for-
mation reflected by osteocalcin. Hypothyroidism is
accompanied by deceleration of bone turnover on the
contrary to thyrotoxicosis. Triiodotyronine was report-
ed to stimulate osteoblasts activity both directly and
indirectly via growth factors and cytokines [12,13].
The action of triiodotyronine on osteoclastic bone
resorption has been suggested to be mediated predom-
inantly by osteoblast-derived osteotrophic cytokines
such as IL-1, IL-6, IL-8 and TNF [12,14]. Data from
the studies on osteoblastic bone marrow stromal cells
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Fig. 1. IL-6 Genotyping of wild-type and IL6KO animals. DNA
electrophoresis on agarose gel. Lanes from left side: lanes 1 to 4 –
wild-type (C57BL/6J) animals, lane 5 – DNA ladder, lanes 6 to 8
– C57BL/6J IL6-/-Kopf mice.
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and osteoblast cell lines have reported that triiodotyro-
nine stimulates IL-6 expression and augments IL-1-
induced stimulation of IL-6 production [15,16]. In the
present study ovariectomy had its strongest impact on
osteocalcin level in hypothyroid IL-6 deficient mice.
Our results suggest that hypothyroidism affects bone
formation only in IL-6 deficient animals and that estro-
gen depletion inhibits this effect. The consequence of
ovariectomy was an increase in sRANKL levels in all
the studied groups. Our results are consistent with data
of Shevde et al. [17] who have shown suppression of
RANKL-induced osteoclast differentiation by estro-
gens via c-Jun repression and results yielded by Shu et
al. [18] who documented reversion of stimulatory
effect of lipopolysaccharide on IL-6 and RANKL
expression after estrogen administration. Ovariectomy
in mice has been shown to increase IL-6 and RANKL
expression in bone tissue [19]. Serum RANKL and
OPG values were lower in all IL-6 deficient group
implying a key regulating role of IL-6 in RANKL-
RANK/OPG balance. On the other hand, sRANKL
elevation in all ovariectomized animals, including
hypothyroid IL-6 deficient mice and increase in OPG
value in hypothyroid ovariectomized IL-6 deficient
animals suggest that estrogens deficit is a strong stim-
ulus for RANKL-RANK/OPG pathway that breaks the
inhibitory influence of hypothyroidism even in IL-6
lacking mice. 
Fig. 2. The individual and median (–––) TRACP 5b serum levels
of ovariectomized hypothyroid and euthyroid WT and IL6KO
mice as well as control hypothyroid and euthyroid WT and
IL6KO mice.
Fig. 3. The individual and median (–––) osteocalcin serum levels
of ovariectomized hypothyroid and euthyroid WT and IL6KO
mice as well as control hypothyroid and euthyroid WT and IL6KO
mice.
Fig. 4. The individual and median (––) RANKL serum levels of
ovariectomized hypothyroid and euthyroid WT and IL6KO mice
as well as control hypothyroid and euthyroid WT and IL6KO
mice.
Fig. 5. The individual and median ( ––– ) osteoprotegerin serum
levels of ovariectomized hypothyroid and euthyroid WT and
IL6KO mice as well as control hypothyroid and euthyroid WT and
IL6KO mice.
The recent discovery of RANK, RANKL and OPG-
members of the TNF and TNF-receptor superfamily
enabled to explain the mechanisms of interaction
between osteclastic and osteoblastic lineage [20].
RANKL-RANK/ OPG pathway was shown to play a
key role in the formation and activation of osteoclasts
in conjunction with various cytokines and calciotropic
hormones. Experimental studies have proved RANKL
expression on osteoblasts and bone marrow stromal
cells and its receptor RANK presence in preosteoclasts
[21]. The interaction between RANKL and RANK
leads to formation and differentiation of osteoclasts by
activation of several transcription factors regulating
osteoclastogenesis [22-24]. OPG is produced by
osteoblasts and is a decoy receptor acting as antagonist
(a soluble receptor that competes with RANK for
RANKL) [25,26]. Up-regulated OPG decreases the
interaction of RANKL with RANK leading to reduc-
tion of osteoclastic bone resorption. Human bone mar-
row cells from early postmenopausal women exhibited
a greater expression of RANKL compared with estro-
gen-treated postmenopausal women [27]. 17β-estradi-
ol has been shown to increase OPG mRNA in human
osteoblastic cell lines [2,24]. Administration of OPG
to ovariectomized rats was documented to prevent
bone loss [21].
Determination of serum levels of RANKL and
OPG in postmenopausal women and their correlation
with bone turnover markers and bone mineral density
are equivocal [23,25,26]. These contradictory findings
may relate to differences ethnicity, study design and
methodology. OPG levels are increased in osteoporot-
ic women reflecting high bone turnover as compared
to nonosteoporotic subjects [27,28]. Association
between serum OPG/sRANKL and incidence of bone
fractures remains controversial [29,30]. We found pos-
itive correlations between TRACP and osteocalcin val-
ues. Moreover sRANKL and osteoprotegerin serum
concentrations were positively correlated with osteo-
calcin concentrations in all studied animals. These
findings may suggest that sRANKL and OPG serum
concentration may reflect bone turnover in general, not
only bone formation or bone resorption. Separate
measurements of sRANKL or OPG seem not to be
useful in assessment of bone metabolism. 
To sum up, the results of the present study suggest
that estrogens deficit is a strong stimulus for RANKL-
RANK/OPG pathway that breaks an inhibitory influ-
ence of hypothyroidism even in IL-6 deficient mice.
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